Pattern of psychotropic prescribing in adults with intellectual disabilities in the community settings in the UK: a cross-sectional view
File(s)1-s2.0-S0891422225000526-main.pdf (497.97 KB)
Published version
Author(s)
Deb, S
Limbu, B
Allgar, V
Type
Journal Article
Abstract
Background
A high proportion of adults with intellectual disabilities receive psychotropic medicines, often in the absence of a mental illness but primarily off-licence for behaviours that challenge.
Aim
To provide a cross-sectional view of the pattern of psychotropic medicine prescriptions with the reasons for their use among adults with intellectual disabilities in community settings in the UK.
Method
We collected psychotropic prescription data on 112 adults with intellectual disabilities who lived in community homes or supported accommodations in the UK. This was done in the context of a feasibility RCT involving a staff training programme, SPECTROM, designed to help reduce the overmedication of adults with intellectual disabilities.
Results
The most commonly prescribed psychotropics were antipsychotics (47 %) followed by antidepressants (23 %), anti-epileptics (13 %) and benzodiazepines (7 %). In 45 % of cases, there was a polypharmacy of more than one psychotropic class of medicines, and in 20 %, a combination of antipsychotics and antidepressants. Antipsychotics were used for severe mental illness only in 19 % but for behaviours that challenge in 40 %, and 17 % of the time for anxiety. Antidepressants were prescribed 47.7 % of the time for depression, 11.4 % for anxiety, and 9 % for behaviours that challenge. Antiepileptics were prescribed more often for behaviours that challenge (40 %) than epilepsy (32 %). In the SPECTROM training group, the antipsychotic dose was reduced in 18.6 % of prescriptions compared with 6.5 % in the non-training group at six months follow-up.
Conclusion
Psychotropic medicines are still prescribed in a high proportion of cases off-licence for behaviours that challenge than mental illness.
A high proportion of adults with intellectual disabilities receive psychotropic medicines, often in the absence of a mental illness but primarily off-licence for behaviours that challenge.
Aim
To provide a cross-sectional view of the pattern of psychotropic medicine prescriptions with the reasons for their use among adults with intellectual disabilities in community settings in the UK.
Method
We collected psychotropic prescription data on 112 adults with intellectual disabilities who lived in community homes or supported accommodations in the UK. This was done in the context of a feasibility RCT involving a staff training programme, SPECTROM, designed to help reduce the overmedication of adults with intellectual disabilities.
Results
The most commonly prescribed psychotropics were antipsychotics (47 %) followed by antidepressants (23 %), anti-epileptics (13 %) and benzodiazepines (7 %). In 45 % of cases, there was a polypharmacy of more than one psychotropic class of medicines, and in 20 %, a combination of antipsychotics and antidepressants. Antipsychotics were used for severe mental illness only in 19 % but for behaviours that challenge in 40 %, and 17 % of the time for anxiety. Antidepressants were prescribed 47.7 % of the time for depression, 11.4 % for anxiety, and 9 % for behaviours that challenge. Antiepileptics were prescribed more often for behaviours that challenge (40 %) than epilepsy (32 %). In the SPECTROM training group, the antipsychotic dose was reduced in 18.6 % of prescriptions compared with 6.5 % in the non-training group at six months follow-up.
Conclusion
Psychotropic medicines are still prescribed in a high proportion of cases off-licence for behaviours that challenge than mental illness.
Date Issued
2025-05-01
Date Acceptance
2025-03-04
Citation
Research in Developmental Disabilities, 2025, 160
ISSN
0891-4222
Publisher
Elsevier BV
Journal / Book Title
Research in Developmental Disabilities
Volume
160
Copyright Statement
© 2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
License URL
Identifier
10.1016/j.ijft.2025.101170
Publication Status
Published
Article Number
104968
Date Publish Online
2025-03-13